FAP mRNA vaccine for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new mRNA vaccine that targets a protein called FAP, which is found in many solid tumors. The vaccine aims to help the immune system fight the cancer. It is for people with advanced solid tumors that have not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have an advanced solid tumor (such as lung, colorectal, or pancreatic cancer) that is confirmed by biopsy.
- Your cancer has not responded to standard treatments or you cannot tolerate them.
- You have at least one tumor that can be measured on scans.
- You are able to take care of yourself (ECOG performance status 0-1) and are expected to live at least 3 more months.
- You agree to use effective birth control during the study and for 4 months after treatment ends.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive treatment (177Lu-OncoFAP-23) alone or combined with an immunotherapy (L19-IL2) for people with advanced solid tumors that have a specific protein called FAP. It's for patients whose cancer has grown despite standard therapies.
This trial is testing an investigational drug called 177Lu-FAP-VG1 for people with advanced solid tumors that have stopped responding to standard therapy. The drug is a type of radiation therapy that targets a protein called FAP, which is found on many cancer cells, to try to shrink the tumor and slow the cancer's growth.
This trial tests a new radioactive drug (225Ac-FAPI-XT) for people with advanced solid tumors that have stopped responding to standard treatments. It targets a protein called FAP found on many cancer cells, which may help deliver radiation directly to the tumor.
This trial is testing an experimental mRNA vaccine (which targets a protein called circFAM53B-219aa found on tumor cells) combined with an immunotherapy drug (anti-PD-1) to treat advanced cancers that have stopped responding to standard treatments. The goal is to see if this combination is safe and effective for people with solid tumors like lung, breast, melanoma, pancreatic, and colon cancer.
This early-stage trial tests a new mRNA-based drug designed to help your immune system fight advanced cancers that haven't responded to standard treatments. The study measures safety, tolerability, and whether it can slow or shrink your tumor.
This trial tests a personalized mRNA vaccine (RH125) designed to train your immune system to attack your cancer. It is for people with advanced solid tumors that have not responded to standard treatments, and it aims to see if the vaccine is safe and helpful.
Hear when a new Advanced Malignant Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.